I happen to think he CEO will be interested in pursuing a major corporate deal or partnership as the preferred way to finance the phase II trials and bring OPT301 to market is the DME trial is successful. But she isn't prepared to give it away to commercialise it.
Seems the market is not fully aware of her ambition.
Industry Mag, page-26
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
87.0¢ |
Change
-0.025(2.79%) |
Mkt cap ! $1.064B | |||
| Open | High | Low | Value | Volume |
| 88.5¢ | 88.5¢ | 85.8¢ | $2.125M | 2.451M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 23 | 32375 | 86.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 87.0¢ | 63293 | 23 |
View Market Depth
| Last trade - 14.48pm 08/10/2024 (20 minute delay) ? |
| OPT (ASX) Chart |